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sirolimus-eluting stents (SES) with durable polymer within the randomized multi-center
all-comers LEADERS trial through 5 years.
Methods: A stratified analysis of clinical outcomes out to 5 years was performed in 1707
patients randomized to BES and SES within the LEADERS all-comers trial with regards
to the presence or absence of diabetes (one of three pre-specified subgroup analyses).
Among diabetics, clinical outcomes were further stratified by insulin dependency.
Results: 414 patients out of 1707 were diabetics (24.3%) with 223 patients in the BES
group and 191 in the SES group. Patients with diabetes were older, more likely to have
hypertension, hypercholesterolemia, history of previous PCI or CABG (all p-values
0.01). Of 414 Diabetic patients, 158 (38%) were insulin-dependent (81 patients in the
BES and 77 in the SES group). At 1 year, the composite endpoint of MACE (cardiac death
(CD), myocardial infarction (MI) or clinically indicated TVR (ci-TVR)) was similar for
DM patients in the BES and SES arms (15.7% vs. 14.7%, p0.75) and for non-DM
patients (8.8% vs 11.2%, p 0.28), with a non-significant interaction. One year outcomes
for CD, MI and ci-TVR were similar in patients with and without DM between the two
groups. As expected, IDDM patients had higher rates of ci-TVR and MACE compared to
NIDDM patients (13.3% vs. 7.0% and 18.4% vs. 13.3%) at 1 year. In the group of
NIDDM patients, no difference in clinical outcomes was observed between two stents.
Within IDDM patients, the use of BES compared to SES resulted in a lower CD rate (0%
vs.6.5%). There was no difference in other clinical endpoints between two stents. The
long-term analysis is currently ongoing.
Conclusions: Patients with IDDM continue to be a challenging population. The 5-year
follow-up will be reported for the 1st time during this meeting.
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Background: We examined whether deployment of coating from drug-eluting stents
(DES) into surrounding neointima could protect a crystalline drug load from luminal
washout and distribute drug more efficiently and uniformly compared to conventional
DES.
Methods: Sirolimus eluting stents (AC-SES: MiStent® Sirolimus-Eluting Stent, Micell
Technologies, Inc., Durham, NC) with an absorbable coating containing PLGA and
crystalline sirolimus were implanted in the coronary arteries of Yucatan mini-swine (1
stent per artery, 1.13:1 B:A). Arteries were harvested after 30d and processed by
histopathology to identify the location, shape and size of tissue-deployed coating.
Computational modeling assessed drug release and distribution surrounding a tissue-
embedded strut comparing fully adherent and 30% deployable coatings.
Results: 30d post implantation into porcine coronary arteries, AC-SES were embedded
within a 4-strut thick neointima and had deployed coating segments as much as 200 m
away from struts (Fig 1). Modeling (Fig 1) predicted highly localized drug distribution
around conformably coated struts. Coating deployment away from the strut increases the
surface area for drug release and distributes drug more uniformly with lower peak values
near each strut and higher levels between struts; peak-trough levels 150m below the IEL
decline at a near constant rate of 1.7 ng/mg per 100 m coating migration.
Conclusions: Deployment of sustained elution coatings flattens vicissitudes in drug
tissue levels, promotes efficient drug delivery, and may reduce potential toxicity.
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Background: In order to develop a biodegradable iron stent, a feasibility study of
biodegradable nitriding iron stent in coronary artery of mini-swine was undergone.
Methods: Eight iron stents (Lifetech Scientific, Shenzhen, China) and eight Vision stents
(Abbott Vascular, CA, USA) as control were randomly implanted into LAD and RCA of
8 healthy mini-swine, respectively. Two stents with same brand were implanted into one
mini-swine. At 4 weeks animals were sacrificed after Optical Coherence Tomography
(OCT) examination; histopathologic examinations were performed.
Results: The mean neointimal thickness (0.460.17mm vs. 0.450.18mm, p0.878),
neointimal area (2.550.91mm2 vs. 3.041.15mm2, p0.360), and percentage of area
restenosis (44.5011.40% vs. 46.0017.95%, p0.845) were not significantly different
between iron stent and Vision stent. There were no inflammation, thrombosis and necrosis
in both groups. The SEM scores(0.751.04 vs. 0.880.99, p0.809) and rate of
proliferating cell nuclear antigen (PCNA) positive staining (19.4311.36% vs.
16.8511.77%, p0.392) had no significant difference between iron and Vision stents.
The percentage of neointimal coverage by SEM (84.3814.50% vs. 65.0022.04%,
p0.057) had a increasing tendency in iron stent group. The minimal lumen diameter
(1.810.18mm vs. 1.760.36mm, p0.785), minimal lumen area (3.340.56mm2 vs.
2.960.82mm2, p0.436) and percentage of stent strut coverage (99.630.38% vs.
99.660.68%, p0.927) by OCT had also no significant difference. Iron stent corrosion
was observed and iron staining in the adjacent tissue of iron stent was positive. Iron
staining was positive in spleens of both groups. No iron overload and abnormal
histopathologic changes were detected in heart, lung, liver, kidney and brain.
Conclusions: The biodegradable iron stent had good biocompatibility. The neointimal
proliferation of iron stent was similar to that of Vision Stent. There were no thrombosis,
inflammation and necrosis in both groups. Percentage of neointimal coverage by SEM
was of 84% and the stent strut coverage by OCT was of 99% in iron stent. Corrosion of
iron stent was observed and there were no signs of iron related organ toxicity.
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Background: The Svelte Drug-Eluting Stent (DES) with Integrated Delivery System
(IDS) is specifically designed for direct stenting, consisting of an ultra low-profile, thin (81
g) CoCr (L-605) stent and fully bioabsorbable, amino acid-based drug carrier eluting
220 g/cm2 of sirolimus mounted on a fixed-wire IDS with a 0.012 shapeable integrated
guidewire tip. The low-compliant delivery balloon is fitted with proximal and distal elastic
balloon control bands (BCBs) to restrict longitudinal balloon growth and allow for
multiple, controlled inflations with minimal vessel contact.
Methods: Svelte DES, all 3.0 x 18mm in size, were implanted in porcine coronary and
internal mammary arteries. Animals were euthanized at various times up to 60 days
following implantation, with vessels and stents examined for sirolimus content. To assess
in-vivo local tissue response, 3.0 x 18mm Svelte DES (n20), drug carrier-only coated
stents (n16), Svelte BMS (n22) and Xience V (n8) were implanted in porcine
coronary arteries for up to 1 year.
Results: Pre-clinical data demonstrate that 80% of the drug was released by 30 days, with
remaining drug eluting by 60 days. Sirolimus levels in the arterial tissue reached peak
levels of 5-6 ng/mg over the first 1-3 days, with levels decreasing to less than 1 ng/mg at
60 days. At 30-days, complete re-endothelialization with Svelte DES was confirmed. At
90-days, a small reduction in inflammatory response (as assessed by mean inflammation
score) with Svelte DES (0.58) compared with Xience V (0.67), drug carrier-only (0.65)
and Svelte BMS (0.72) was observed (pNS). Svelte DES inflammation was character-
ized as lymphohistiocytic with few eosinophils and giant cells with micro-granuloma
formation around the stent struts. SEM analysis showed no evidence of thrombus
formation. The bio-erodible amino acid based carrier appears to possess high mechanical
integrity and low-inflammatory properties.
Conclusions: In-vivo drug elution kinetics and tissue and blood levels of sirolimus are
reported, as are histopathology and carrier erosion kinetics through 1-year, demonstrating
low inflammatory response to the drug carrier and suppressed hyperplastic response
through 390-days.
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